Dengue vaccine

Kathryn Dzintars, PharmD, BCPS


  • Dengvaxia®, or the Dengue Tetravalent Vaccine, is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3 and 4.
    • Approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection AND who lived in an endemic area.
    • The vaccine is built on a yellow fever backbone component.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 17, 2023